Ahmed S. Abdelsamie
Research Subjects
Ahmed S. Abdelsamie has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Martin Frotscher
Department of Pharmaceutical and Medicinal Chemistry , Saarland University , 66123 Saarbrücken , Germany
11 shared publications - Mohamed Salah
Department of Pharmaceutical and Medicinal Chemistry , Saarland University , 66123 Saarbrücken , Germany
8 shared publications - Chris J. van Koppen
Department of Pharmaceutical and Medicinal Chemistry, Universitätscampus C2.3, 66123 Saarbrücken, Germany
6 shared publications Matthias W. Laschke
Institute for Clinical and Experimental Surgery, Saarland University, 66421 Homburg, Germany
5 shared publications- Rolf Wolfgang Hartmann
Department of Drug Design and Optimization Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) Helmholtz Centre for Infection Research (HZI) Campus E8 1 66123 Saarbrücken Germany
5 shared publications Hoda I. El Diwani
4 shared publications
Latest Publications
- Open Access
- 5 February 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (4) , 4160-4186
Multiparameter Optimization of Pseudomonas aeruginosa Elastase Inhibitors for Systemic Administration
Targeting the extracellular protease elastase (LasB) of the high-priority pathogen Pseudomonas aeruginosa is a promising strategy to develop second-generation, narrow-spectrum antibiotics with a novel mode of action. P. aeruginosa is responsible for a variety of infections, particularly of the lung. Herein, we report the structure-based optimization of a previously reported potent and selective phosphonate-based LasB inhibitor scaffold. Having improved the activity while maintaining high selectivity and favorable ADMET properties, we also demonstrate, for the first time within this scaffold, that intravenous administration leads to favorable lung retention. We could rationally align this with in vitro plasma protein binding. We further observed a link between physicochemical properties like logD7.4 and protein binding, including surfactant proteins that can impair compound activity in the lung. This multiparameter optimization paves the way for the exploration of additional indications requiring systemic treatment, such as hospital-acquired or ventilator-associated pneumonia.
- 5 February 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (4) , 4160-4186
Open AccessMultiparameter Optimization of Pseudomonas aeruginosa Elastase Inhibitors for Systemic Administration
Targeting the extracellular protease elastase (LasB) of the high-priority pathogen Pseudomonas aeruginosa is a promising strategy to develop second-generation, narrow-spectrum antibiotics with a novel mode of action. P. aeruginosa is responsible for a variety of infections, particularly of the lung. Herein, we report the structure-based optimization of a previously reported potent and selective phosphonate-based LasB inhibitor scaffold. Having improved the activity while maintaining high selectivity and favorable ADMET properties, we also demonstrate, for the first time within this scaffold, that intravenous administration leads to favorable lung retention. We could rationally align this with in vitro plasma protein binding. We further observed a link between physicochemical properties like logD7.4 and protein binding, including surfactant proteins that can impair compound activity in the lung. This multiparameter optimization paves the way for the exploration of additional indications requiring systemic treatment, such as hospital-acquired or ventilator-associated pneumonia.
- 22 April 2024
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1311
Synthesis, biological evaluation, and docking studies of pyrazole-linked benzothiazole hybrids as promising anti-TB agents
- 22 April 2024
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1311
Synthesis, biological evaluation, and docking studies of pyrazole-linked benzothiazole hybrids as promising anti-TB agents
- Open Access
- 27 October 2023
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 9 (12) , 2205-2215
Inhibitors of the Elastase LasB for the Treatment of Pseudomonas aeruginosa Lung Infections
Infections caused by the Gram-negative pathogen Pseudomonas aeruginosa are emerging worldwide as a major threat to human health. Conventional antibiotic monotherapy suffers from rapid resistance development, underlining urgent need for novel treatment concepts. Here, we report on a nontraditional approach to combat P. aeruginosa-derived infections by targeting its main virulence factor, the elastase LasB. We discovered a new chemical class of phosphonates with an outstanding in vitro ADMET and PK profile, auspicious activity both in vitro and in vivo. We established the mode of action through a cocrystal structure of our lead compound with LasB and in several in vitro and ex vivo models. The proof of concept of a combination of our pathoblocker with levofloxacin in a murine neutropenic lung infection model and the reduction of LasB protein levels in blood as a proof of target engagement demonstrate the great potential for use as an adjunctive treatment of lung infections in humans.
- 27 October 2023
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 9 (12) , 2205-2215
Open AccessInhibitors of the Elastase LasB for the Treatment of Pseudomonas aeruginosa Lung Infections
Infections caused by the Gram-negative pathogen Pseudomonas aeruginosa are emerging worldwide as a major threat to human health. Conventional antibiotic monotherapy suffers from rapid resistance development, underlining urgent need for novel treatment concepts. Here, we report on a nontraditional approach to combat P. aeruginosa-derived infections by targeting its main virulence factor, the elastase LasB. We discovered a new chemical class of phosphonates with an outstanding in vitro ADMET and PK profile, auspicious activity both in vitro and in vivo. We established the mode of action through a cocrystal structure of our lead compound with LasB and in several in vitro and ex vivo models. The proof of concept of a combination of our pathoblocker with levofloxacin in a murine neutropenic lung infection model and the reduction of LasB protein levels in blood as a proof of target engagement demonstrate the great potential for use as an adjunctive treatment of lung infections in humans.
- 27 June 2023
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (13) , 8975-8992
Potent Dual Inhibitors of Steroid Sulfatase and 17β-Hydroxysteroid Dehydrogenase Type 1 with a Suitable Pharmacokinetic Profile for In Vivo Proof-of-Principle Studies in an Endometriosis Mouse Model
Treating estrogen-dependent diseases like endometriosiswith drugssuppressing local estrogen activation may be superior to existingendocrine therapies. Steroid sulfatase (STS) and 17 & beta;-hydroxysteroiddehydrogenase type 1 (17 & beta;-HSD1) are key enzymes of local estrogenactivation. We describe the rational design, synthesis, and biologicalprofilation of furan-based compounds as a novel class of dual STS/17 & beta;-HSD1inhibitors (DSHIs). In T47D cells, compound 5 showedirreversible inhibition of STS and potent, reversible inhibition of17 & beta;-HSD1. It was selective over 17 & beta;-HSD2 and displayedhigh metabolic stabilities in human and mouse liver S9 fractions.No effect on cell viability was detected up to 31 & mu;M (HEK293)and 23 & mu;M (HepG2), respectively, and there was no activationof the aryl hydrocarbon receptor (AhR) up to 3.16 & mu;M. Singledaily application to mice revealed steady-state plasma levels highenough to make this compound eligible for an in vivo proof-of-principle study in a mouse endometriosis model.
- 27 June 2023
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (13) , 8975-8992
Potent Dual Inhibitors of Steroid Sulfatase and 17β-Hydroxysteroid Dehydrogenase Type 1 with a Suitable Pharmacokinetic Profile for In Vivo Proof-of-Principle Studies in an Endometriosis Mouse Model
Treating estrogen-dependent diseases like endometriosiswith drugssuppressing local estrogen activation may be superior to existingendocrine therapies. Steroid sulfatase (STS) and 17 & beta;-hydroxysteroiddehydrogenase type 1 (17 & beta;-HSD1) are key enzymes of local estrogenactivation. We describe the rational design, synthesis, and biologicalprofilation of furan-based compounds as a novel class of dual STS/17 & beta;-HSD1inhibitors (DSHIs). In T47D cells, compound 5 showedirreversible inhibition of STS and potent, reversible inhibition of17 & beta;-HSD1. It was selective over 17 & beta;-HSD2 and displayedhigh metabolic stabilities in human and mouse liver S9 fractions.No effect on cell viability was detected up to 31 & mu;M (HEK293)and 23 & mu;M (HepG2), respectively, and there was no activationof the aryl hydrocarbon receptor (AhR) up to 3.16 & mu;M. Singledaily application to mice revealed steady-state plasma levels highenough to make this compound eligible for an in vivo proof-of-principle study in a mouse endometriosis model.
- 22 August 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (17) , 11726-11744
Dual Targeting of Steroid Sulfatase and 17β-Hydroxysteroid Dehydrogenase Type 1 by a Novel Drug-Prodrug Approach: A Potential Therapeutic Option for the Treatment of Endometriosis
A novel approach for the dual inhibition of steroid sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1(17β HSD1) by a single drug was explored, starting from in-house 17β HSD1 inhibitors via masking their phenolic OH group with a sulfamate ester. The sulfamates were intentionally designed as drugs for the inhibition of STS and, at the same time, prodrugs for 17β-HSD1 inhibition ("drug-prodrug approach"). The most promising sulfamates 13, 16, 18-20, 22-24, 36, and 37 showed nanomolar IC50 values for STS inhibition in a cellular assay and their corresponding phenols displayed potent 17β-HSD1 inhibition in cell-free and cellular assays, high selectivity over 17β-HSD2, reasonable metabolic stability, and low estrogen receptor α affinity. A close relationship was found between the liberation of the phenolic compound by sulfamate hydrolysis and 17β-HSD1 inactivation. These results showed that the envisaged drug-prodrug concept was successfully implemented. The novel compounds constitute a promising class of therapeutics for the treatment of endometriosis and other estrogen-dependent diseases.
- 22 August 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (17) , 11726-11744
Dual Targeting of Steroid Sulfatase and 17β-Hydroxysteroid Dehydrogenase Type 1 by a Novel Drug-Prodrug Approach: A Potential Therapeutic Option for the Treatment of Endometriosis
A novel approach for the dual inhibition of steroid sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1(17β HSD1) by a single drug was explored, starting from in-house 17β HSD1 inhibitors via masking their phenolic OH group with a sulfamate ester. The sulfamates were intentionally designed as drugs for the inhibition of STS and, at the same time, prodrugs for 17β-HSD1 inhibition ("drug-prodrug approach"). The most promising sulfamates 13, 16, 18-20, 22-24, 36, and 37 showed nanomolar IC50 values for STS inhibition in a cellular assay and their corresponding phenols displayed potent 17β-HSD1 inhibition in cell-free and cellular assays, high selectivity over 17β-HSD2, reasonable metabolic stability, and low estrogen receptor α affinity. A close relationship was found between the liberation of the phenolic compound by sulfamate hydrolysis and 17β-HSD1 inactivation. These results showed that the envisaged drug-prodrug concept was successfully implemented. The novel compounds constitute a promising class of therapeutics for the treatment of endometriosis and other estrogen-dependent diseases.
- 1 September 2019
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 192, 105405
Effects of 17β-HSD2 inhibition in bones on osteoporosis based on an animal rat model
- 1 September 2019
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 192, 105405
Effects of 17β-HSD2 inhibition in bones on osteoporosis based on an animal rat model
- 1 September 2019
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 178, 93-107
Development of potential preclinical candidates with promising in vitro ADME profile for the inhibition of type 1 and type 2 17β-Hydroxysteroid dehydrogenases: Design, synthesis, and biological evaluation
- 1 September 2019
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 178, 93-107
Development of potential preclinical candidates with promising in vitro ADME profile for the inhibition of type 1 and type 2 17β-Hydroxysteroid dehydrogenases: Design, synthesis, and biological evaluation
- 25 July 2019
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 62 (15) , 7289-7301
Design, Synthesis, and Biological Characterization of Orally Active 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors Targeting the Prevention of Osteoporosis
Osteoporosis is predominantly treated with drugs that inhibit further bone resorption due to estrogen deficiency. Yet, osteoporosis drugs that not only inhibit bone resorption but also stimulate bone formation, such as potentially inhibitors of 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2), may be more efficacious in the treatment of osteoporosis. Blockade of 17β-HSD2 is thought to increase intracellular estradiol and testosterone in bone, thereby inhibiting bone resorption by osteoclasts and stimulating bone formation by osteoblasts, respectively. We here describe the design, synthesis, and biological characterization of a novel bicyclic-substituted hydroxyphenylmethanone 17β-HSD2 inhibitor (compound 24). Compound 24 is a nanomolar potent inhibitor of human 17β-HSD2 (IC50 of 6.1 nM) and rodent 17β-HSD2 with low in vitro cellular toxicity, devoid of detectable estrogen receptor α affinity, displays high aqueous solubility and in vitro metabolic stability, and has an excellent oral pharmacokinetic profile for testing in a rat osteoporosis model. Administration of 24 in a rat osteoporosis model demonstrates its bone-sparing efficacy.
- 25 July 2019
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 62 (15) , 7289-7301
Design, Synthesis, and Biological Characterization of Orally Active 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors Targeting the Prevention of Osteoporosis
Osteoporosis is predominantly treated with drugs that inhibit further bone resorption due to estrogen deficiency. Yet, osteoporosis drugs that not only inhibit bone resorption but also stimulate bone formation, such as potentially inhibitors of 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2), may be more efficacious in the treatment of osteoporosis. Blockade of 17β-HSD2 is thought to increase intracellular estradiol and testosterone in bone, thereby inhibiting bone resorption by osteoclasts and stimulating bone formation by osteoblasts, respectively. We here describe the design, synthesis, and biological characterization of a novel bicyclic-substituted hydroxyphenylmethanone 17β-HSD2 inhibitor (compound 24). Compound 24 is a nanomolar potent inhibitor of human 17β-HSD2 (IC50 of 6.1 nM) and rodent 17β-HSD2 with low in vitro cellular toxicity, devoid of detectable estrogen receptor α affinity, displays high aqueous solubility and in vitro metabolic stability, and has an excellent oral pharmacokinetic profile for testing in a rat osteoporosis model. Administration of 24 in a rat osteoporosis model demonstrates its bone-sparing efficacy.
- Open Access
- 1 June 2019
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 489, 66-81
Inhibitors of 17β-hydroxysteroid dehydrogenase type 1, 2 and 14: Structures, biological activities and future challenges
- 1 June 2019
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 489, 66-81
Open AccessInhibitors of 17β-hydroxysteroid dehydrogenase type 1, 2 and 14: Structures, biological activities and future challenges
- 15 January 2019
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 62 (3) , 1362-1372
Targeted Endocrine Therapy: Design, Synthesis, and Proof-of-Principle of 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors in Bone Fracture Healing
Current therapies of steroid hormone-dependent diseases predominantly alter steroid hormone concentrations (or their actions) in plasma, in target and nontarget tissues alike, rather than in target organs only. Targeted therapy through the inhibition of steroidogenic enzymes may pose an attractive alternative with much less side effects. Here, we describe the design of a nanomolar potent 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitor (compound 15) and successful targeted intracrine therapy in a mouse bone fracture model. Blockade of 17β-HSD2 in bone is thought to increase intracellular estradiol (E2) and testosterone (T), which thereby inhibits bone resorption by osteoclasts and stimulates bone formation by osteoblasts, respectively. Administration of compound 15 in the mouse fracture model strongly increases the mechanical stability of the healing fractured bone because of a larger periosteal callus with newly formed bone without changing the plasma E2 and T concentrations. Steroidogenic 17β-HSD2 inhibition thus enables targeted intracrine therapy.
- 15 January 2019
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 62 (3) , 1362-1372
Targeted Endocrine Therapy: Design, Synthesis, and Proof-of-Principle of 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors in Bone Fracture Healing
Current therapies of steroid hormone-dependent diseases predominantly alter steroid hormone concentrations (or their actions) in plasma, in target and nontarget tissues alike, rather than in target organs only. Targeted therapy through the inhibition of steroidogenic enzymes may pose an attractive alternative with much less side effects. Here, we describe the design of a nanomolar potent 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitor (compound 15) and successful targeted intracrine therapy in a mouse bone fracture model. Blockade of 17β-HSD2 in bone is thought to increase intracellular estradiol (E2) and testosterone (T), which thereby inhibits bone resorption by osteoclasts and stimulates bone formation by osteoblasts, respectively. Administration of compound 15 in the mouse fracture model strongly increases the mechanical stability of the healing fractured bone because of a larger periosteal callus with newly formed bone without changing the plasma E2 and T concentrations. Steroidogenic 17β-HSD2 inhibition thus enables targeted intracrine therapy.